Literature DB >> 23286851

New therapeutic strategies in HCV: polymerase inhibitors.

Ludmila Gerber1, Tania M Welzel, Stefan Zeuzem.   

Abstract

The characterization of the viral life cycle facilitated the development of directly acting antiviral drugs. Among those, several inhibitors of the viral RNA-dependent RNA polymerase have proven effectiveness in clinical trials. The characteristics of different nucleos(t)ide and non-nucleoside polymerase inhibitors, as well as their clinical applications and combinations with other classes of directly acting antiviral drugs are reviewed herein.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23286851     DOI： 10.1111/liv.12068

Source DB:  PubMed          Journal:  Liver Int        ISSN： 1478-3223            Impact factor:   5.828


  18 in total

1.  Structure-Activity Relationship Study of QL47: A Broad-Spectrum Antiviral Agent.

Authors:  Yanke Liang; Melissanne de Wispelaere; Margot Carocci; Qingsong Liu; Jinhua Wang; Priscilla L Yang; Nathanael S Gray
Journal:  ACS Med Chem Lett       Date:  2017-02-03       Impact factor: 4.345

2.  HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis.

Authors:  Mei-Hsuan Lee; Tiffany I Hsiao; Shreenidhi R Subramaniam; An K Le; Vinh D Vu; Huy N Trinh; Jian Zhang; Mingjuan Jin; Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Mindie H Nguyen
Journal:  Am J Gastroenterol       Date:  2017-04-25       Impact factor: 10.864

3.  Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors.

Authors:  Lucio Boglione; Simone Mornese Pinna; Chiara Simona Cardellino; Amedeo De Nicolò; Jessica Cusato; Chiara Carcieri; Giuseppe Cariti; Giovanni Di Perri; Antonio D'Avolio
Journal:  Infection       Date:  2016-11-16       Impact factor: 3.553

Review 4.  Hepatitis C genotype 6: A concise review and response-guided therapy proposal.

Authors:  Chalermrat Bunchorntavakul; Disaya Chavalitdhamrong; Tawesak Tanwandee
Journal:  World J Hepatol       Date:  2013-09-27

5.  Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir.

Authors:  Elodie Valade; Thomas N Kakuda; Matthew W McClure; Christopher Westland; Belén Valenzuela; Sivi Ouwerkerk-Mahadevan; Juan José Perez-Ruixo; Oliver Ackaert
Journal:  AAPS J       Date:  2018-10-24       Impact factor: 4.009

6.  Antiviral Nucleotide Incorporation by Recombinant Human Mitochondrial RNA Polymerase Is Predictive of Increased In Vivo Mitochondrial Toxicity Risk.

Authors:  Martijn Fenaux; Xiaodong Lin; Fumiaki Yokokawa; Zachary Sweeney; Oliver Saunders; Lili Xie; Siew Pheng Lim; Marianne Uteng; Kyoko Uehara; Robert Warne; Wang Gang; Christopher Jones; Satya Yendluri; Helen Gu; Keith Mansfield; Julie Boisclair; Tycho Heimbach; Alexandre Catoire; Kathryn Bracken; Margaret Weaver; Heinz Moser; Weidong Zhong
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

Review 7.  Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals.

Authors:  Asma Ahmed; Daniel J Felmlee
Journal:  Viruses       Date:  2015-12-18       Impact factor: 5.048

Review 8.  Sofosbuvir, a Significant Paradigm Change in HCV Treatment.

Authors:  Thomas McQuaid; Carolyn Savini; Star Seyedkazemi
Journal:  J Clin Transl Hepatol       Date:  2015-03-15

9.  Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis.

Authors:  Xiwei Wang; Fen Liu; Fang Wei; Hong Ren; Huaidong Hu
Journal:  PLoS One       Date:  2014-06-25       Impact factor: 3.240

10.  The versatile nature of the 6-aminoquinolone scaffold: identification of submicromolar hepatitis C virus NS5B inhibitors.

Authors:  Giuseppe Manfroni; Rolando Cannalire; Maria Letizia Barreca; Neerja Kaushik-Basu; Pieter Leyssen; Johan Winquist; Nunzio Iraci; Dinesh Manvar; Jan Paeshuyse; Rupa Guhamazumder; Amartya Basu; Stefano Sabatini; Oriana Tabarrini; U Helena Danielson; Johan Neyts; Violetta Cecchetti
Journal:  J Med Chem       Date:  2013-11-06       Impact factor: 7.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.